Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint ...

Syndax Pharmaceuticals, Inc. announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualized rate of decline in forced ...

Bristol Myers Squibb has reported phase 3 results with a new type of drug for idiopathic pulmonary fibrosis (IPF) that could ...

A new review proposes that interferon-gamma acts as a regulatory hub connecting immune activation, inflammatory amplification ...

A diagnosis of pulmonary fibrosis gave Monica Reyes, 50, a new outlook on life and how to help the patients she works with.

Beyond its approved use, Axatilimab is currently being studied in frontline treatment settings for chronic graft-versus-host disease (cGVHD), including a Phase 2 combination trial with ruxolitinib and ...

The revelation of a patient death in Bristol Myers Squibb’s phase 3 trial of a potential pulmonary fibrosis treatment has ...

Bristol Myers Squibb said the findings reinforce the potential of admilparant as a clinically meaningful treatment for idiopathic pulmonary fibrosis, a type of pulmonary fibrosis with no identifiable ...

PET/CT in scarred lung tissue to clinical severity and hints at faster disease progression in idiopathic pulmonary fibrosis.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...